OBJECTIVE: Treating acute hepatitis C (HCV) in injection drug users (IDUs) is complicated by a high prevalence of psychiatric comorbidities that may lead to increased risk for depressive complications of interferon treatment. Effective screening strategies are needed to help non-psychiatric clinicians identify depressive disorders. METHODS:Thirty IDUs with acute HCV completed the Beck Depression Inventory (BDI), underwent a psychiatric examination, and were randomized to 24 weeks of pegylated interferon treatment (IFA) or observation (OBS). Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of the BDI for diagnosing depression (with a cutoff >10) were calculated. The psychiatrist's diagnosis was used as the gold standard. Depression severity was assessed over time with the BDI. RESULTS:Forty-seven percent of individuals met criteria for a depressive disorder. Sensitivity (91%) and NPV (92%) were high for the BDI; specificity (58%) and PPV (56%) were low. BDI worsened in 2 patients completing the study (one IFA, one OBS); two IFA patients were discontinued for possible depression-related complications. At baseline, subject-rated fatigue was associated with alanine aminotransferase level. CONCLUSION: The BDI is an adequate tool for ruling out depressive disorders in active IDUs with acute HCV, but specificity is low. Psychiatric consultation is recommended for all active IDUs being considered for acute HCV treatment. Copyright 2010 Elsevier Inc. All rights reserved.
RCT Entities:
OBJECTIVE: Treating acute hepatitis C (HCV) in injection drug users (IDUs) is complicated by a high prevalence of psychiatric comorbidities that may lead to increased risk for depressive complications of interferon treatment. Effective screening strategies are needed to help non-psychiatric clinicians identify depressive disorders. METHODS: Thirty IDUs with acute HCV completed the Beck Depression Inventory (BDI), underwent a psychiatric examination, and were randomized to 24 weeks of pegylated interferon treatment (IFA) or observation (OBS). Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of the BDI for diagnosing depression (with a cutoff >10) were calculated. The psychiatrist's diagnosis was used as the gold standard. Depression severity was assessed over time with the BDI. RESULTS: Forty-seven percent of individuals met criteria for a depressive disorder. Sensitivity (91%) and NPV (92%) were high for the BDI; specificity (58%) and PPV (56%) were low. BDI worsened in 2 patients completing the study (one IFA, one OBS); two IFA patients were discontinued for possible depression-related complications. At baseline, subject-rated fatigue was associated with alanine aminotransferase level. CONCLUSION: The BDI is an adequate tool for ruling out depressive disorders in active IDUs with acute HCV, but specificity is low. Psychiatric consultation is recommended for all active IDUs being considered for acute HCV treatment. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: D L Musselman; D H Lawson; J F Gumnick; A K Manatunga; S Penna; R S Goodkin; K Greiner; C B Nemeroff; A H Miller Journal: N Engl J Med Date: 2001-03-29 Impact factor: 91.245
Authors: John G Gunderson; Leslie C Morey; Robert L Stout; Andrew E Skodol; M Tracie Shea; Thomas H McGlashan; Mary C Zanarini; Carlos M Grilo; Charles A Sanislow; Shirley Yen; Maria T Daversa; Donna S Bender Journal: J Clin Psychiatry Date: 2004-08 Impact factor: 4.384
Authors: E Jaeckel; M Cornberg; H Wedemeyer; T Santantonio; J Mayer; M Zankel; G Pastore; M Dietrich; C Trautwein; M P Manns Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Benjamin J Morasco; Muhamad Aly Rifai; Jennifer M Loftis; David W Indest; James Kelly Moles; Peter Hauser Journal: J Affect Disord Date: 2007-02-09 Impact factor: 4.839
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: Leonora Franke; Eric Therstappen; Beate Schlosser; Michael Biermer; Thomas Berg; Martin Schäfer; Petra Arck; Ralf Uebelhack; Astrid Friebe Journal: Depress Res Treat Date: 2014-03-20